AU2008331984B2 - Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms - Google Patents

Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms Download PDF

Info

Publication number
AU2008331984B2
AU2008331984B2 AU2008331984A AU2008331984A AU2008331984B2 AU 2008331984 B2 AU2008331984 B2 AU 2008331984B2 AU 2008331984 A AU2008331984 A AU 2008331984A AU 2008331984 A AU2008331984 A AU 2008331984A AU 2008331984 B2 AU2008331984 B2 AU 2008331984B2
Authority
AU
Australia
Prior art keywords
compound
treatment
thrombus
day
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008331984A
Other languages
English (en)
Other versions
AU2008331984A1 (en
Inventor
Jean-Baptiste Michel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008331984A1 publication Critical patent/AU2008331984A1/en
Application granted granted Critical
Publication of AU2008331984B2 publication Critical patent/AU2008331984B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008331984A 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms Active AU2008331984B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301616.4 2007-12-03
EP07301616 2007-12-03
PCT/SE2008/051386 WO2009072967A1 (en) 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms

Publications (2)

Publication Number Publication Date
AU2008331984A1 AU2008331984A1 (en) 2009-06-11
AU2008331984B2 true AU2008331984B2 (en) 2012-08-16

Family

ID=40717966

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008331984A Active AU2008331984B2 (en) 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms

Country Status (24)

Country Link
US (2) US20100298350A1 (https=)
EP (1) EP2229172B1 (https=)
JP (1) JP5701060B2 (https=)
KR (1) KR101563757B1 (https=)
CN (2) CN103919781A (https=)
AU (1) AU2008331984B2 (https=)
BR (1) BRPI0819458A2 (https=)
CA (1) CA2707488C (https=)
CY (1) CY1115760T1 (https=)
DK (1) DK2229172T3 (https=)
EA (1) EA201000928A1 (https=)
ES (1) ES2522317T3 (https=)
HR (1) HRP20141081T1 (https=)
IL (1) IL205613A (https=)
MX (1) MX2010006101A (https=)
MY (1) MY159656A (https=)
NZ (1) NZ585513A (https=)
PL (1) PL2229172T3 (https=)
PT (1) PT2229172E (https=)
RS (1) RS53635B1 (https=)
SI (1) SI2229172T1 (https=)
UA (1) UA100864C2 (https=)
WO (1) WO2009072967A1 (https=)
ZA (1) ZA201003599B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034283A1 (en) * 1998-12-04 2000-06-15 Astrazeneca Ab Novel triazolo(4,5-d)pyrimidine compounds
WO2001092262A1 (en) * 2000-06-02 2001-12-06 Astrazeneca Ab New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
WO2002096428A1 (en) * 2001-05-31 2002-12-05 Astrazeneca Ab Pharmaceutical combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199800019T1 (xx) * 1995-07-11 1998-05-21 Astra Pharmaceuticals Limited Trombosit topaklanmas�n� �nleyici yeni maddeler.
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034283A1 (en) * 1998-12-04 2000-06-15 Astrazeneca Ab Novel triazolo(4,5-d)pyrimidine compounds
WO2001092262A1 (en) * 2000-06-02 2001-12-06 Astrazeneca Ab New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
WO2002096428A1 (en) * 2001-05-31 2002-12-05 Astrazeneca Ab Pharmaceutical combinations

Also Published As

Publication number Publication date
KR101563757B1 (ko) 2015-10-27
EP2229172A4 (en) 2012-12-26
IL205613A0 (en) 2010-11-30
MX2010006101A (es) 2010-10-04
BRPI0819458A2 (pt) 2015-05-05
JP5701060B2 (ja) 2015-04-15
NZ585513A (en) 2012-07-27
EA201000928A1 (ru) 2010-12-30
ES2522317T3 (es) 2014-11-14
CY1115760T1 (el) 2017-01-25
CN101883565A (zh) 2010-11-10
CA2707488A1 (en) 2009-06-11
PT2229172E (pt) 2014-11-03
US20100298350A1 (en) 2010-11-25
RS53635B1 (sr) 2015-04-30
DK2229172T3 (da) 2014-11-10
EP2229172A1 (en) 2010-09-22
JP2011505417A (ja) 2011-02-24
CN103919781A (zh) 2014-07-16
HK1148195A1 (en) 2011-09-02
US20150272955A1 (en) 2015-10-01
SI2229172T1 (sl) 2014-12-31
AU2008331984A1 (en) 2009-06-11
PL2229172T3 (pl) 2015-01-30
MY159656A (en) 2017-01-13
IL205613A (en) 2015-04-30
HRP20141081T1 (hr) 2015-01-02
WO2009072967A1 (en) 2009-06-11
EP2229172B1 (en) 2014-09-10
ZA201003599B (en) 2012-10-31
KR20100099175A (ko) 2010-09-10
UA100864C2 (uk) 2013-02-11
CA2707488C (en) 2015-07-28

Similar Documents

Publication Publication Date Title
US11478440B2 (en) Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
JP5819328B2 (ja) ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療
US20040110833A1 (en) Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
AU2008331984B2 (en) Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms
CA2681597A1 (en) Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
JP2005523263A (ja) 瘢痕化及び繊維症の治療におけるｐｄｅ５阻害剤の使用
Acun et al. The effect of single-dose intraperitoneal bevacizumab on peritoneal adhesion formation
US20090075949A1 (en) Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
EP2344149A1 (en) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
US20210379078A1 (en) Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor
EP1603573B1 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
HK1148195B (en) Ticagrelor for treatment of abdominal aortic aneurysms
Ezeamuzie et al. Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251)–A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation
Noji et al. Treatment with an adenosine uptake inhibitor attenuates glomerulonephritis in mice
US20130095059A1 (en) Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model
WO2026050288A1 (en) Modulating the acute foreign body reaction to reduce stenosis
EP1385504A1 (en) Method of inhibiting adhesion formation
AU2002305164A1 (en) Method of inhibiting adhesion formation
Nieuwenhuis et al. Agents interfering with the platelet-vessel wall interaction
HK1224599A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
HK1224599A1 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
JP2005298336A (ja) 炎症性疾患治療用薬剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)